The eye health company Bausch + Lomb Corp. has announced it will report its second-quarter financial results for 2026 on July 29, before the U.S. stock market opens. The company's management team will host a conference call at 8:00 a.m. Eastern Time that day to discuss the performance and take questions from financial analysts.

Bausch + Lomb Corp. operates across three main segments: vision care, ophthalmic pharmaceuticals, and surgical devices, with its products sold in over 100 countries and territories worldwide. The company completed its initial public offering, listing on both the New York Stock Exchange and the Toronto Stock Exchange in 2022.

For the first quarter ended March 31, the company reported revenue of $1.23 billion, representing an increase of approximately 6% year-over-year, driven largely by continued growth in its contact lens and surgical businesses. In its prior annual outlook, the company projected full-year 2026 revenue growth would remain in the range of 5% to 7%. The market is keenly focused on whether the second-quarter figures will sustain this growth momentum, particularly in emerging markets such as Asia-Pacific and Latin America.

Investors will also be watching for any updates to the company's full-year guidance. Bausch + Lomb Corp. has previously indicated that full-year profit growth may slightly lag revenue growth due to factors like rising raw material costs and foreign exchange volatility in certain markets. The company is working to counter these headwinds through product portfolio optimization and improvements in operational efficiency. Additionally, recent progress in the development of its next-generation intraocular lens product is likely to be a topic of discussion during the call.

The upcoming earnings release coincides with a continued recovery in global demand for ophthalmic surgical procedures. According to data from industry research firms, global cataract surgery volumes are forecast to grow by about 8% in 2026, while demand for laser refractive surgery is also steadily rebounding. As one of the world's three leading suppliers of ophthalmic surgical devices, Bausch + Lomb Corp. is positioned to benefit from this trend.

The company noted that a live webcast of the conference call will be available on its investor relations website, with a replay provided following the event. Investors and analysts can participate in the Q&A session via the provided dial-in number. Detailed participation instructions will be published on the company's website prior to the earnings release.